Eikon Therapeutics (EIKN) CFO awarded stock options for 67,044 shares

Rhea-AI Filing Summary

Eikon Therapeutics Chief Financial Officer receives new stock option grant. CFO Alfred Lloyd Bowie Jr. was granted stock options for 67,044 shares of Eikon Therapeutics, Inc. common stock on March 2, 2026, at an exercise price of $0.00 per share, recorded as a grant or award acquisition.

The option vests over four years: 1/48th of the underlying shares vest on each monthly anniversary of the vesting start date for 48 months, provided he continues in service through each vesting date. Following this grant, he directly holds options covering 67,044 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bowie Alfred Lloyd Jr.

(Last) (First) (Middle)

C/O EIKON THERAPEUTICS, INC.

230 HARRIET TUBMAN WAY

(Street)

MILLBRAE CA 94030

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Eikon Therapeutics, Inc. [ EIKN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$14.88	03/02/2026		A		67,044		(1)	03/01/2036	Common Stock	67,044	$0	67,044	D

Explanation of Responses:

1. 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date.

	/s/ Benjamin Thorner, Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Eikon Therapeutics (EIKN) report for its CFO?

Eikon Therapeutics reported that CFO Alfred Lloyd Bowie Jr. received a grant of stock options for 67,044 shares on March 2, 2026. The options were recorded as a grant or award acquisition with an exercise price of $0.00 per share, increasing his directly held options to 67,044 shares.

How many Eikon Therapeutics (EIKN) stock options were granted to the CFO?

The CFO received stock options covering 67,044 shares of Eikon Therapeutics common stock. These options were granted as a single award and are scheduled to vest in equal monthly installments over 48 months, subject to his continued service with the company through each vesting date.

What is the vesting schedule for the Eikon Therapeutics (EIKN) CFO’s new option grant?

The option vests monthly over four years. Specifically, 1/48th of the 67,044 underlying shares will vest on each monthly anniversary of the vesting start date for 48 months, provided the CFO continues serving the company through each applicable vesting date.

What is the exercise price of the Eikon Therapeutics (EIKN) CFO’s new stock options?

The reported exercise price for the CFO’s stock option grant is $0.00 per share. This means the options were granted without an exercise cost in the filing data, and vest over time according to a 48‑month monthly vesting schedule tied to continued service.

How did this option grant change the Eikon Therapeutics (EIKN) CFO’s holdings?

After the transaction, the CFO directly holds options for 67,044 shares of Eikon Therapeutics common stock. The filing shows this full amount as the total derivative securities owned following the grant, reflecting his entire reported option position after the award.

Is the Eikon Therapeutics (EIKN) CFO’s option grant subject to continued employment?

Yes. The filing states that vesting is conditioned on continued service. Each monthly tranche, representing 1/48th of the 67,044 underlying shares, will vest only if the CFO remains in service with Eikon Therapeutics through the applicable monthly vesting date.